Oncolytic vaccinia virus armed with 4–1BBL elicits potent and safe antitumor immunity and enhances the therapeutic efficiency of PD-1/PD-L1 blockade in a pancreatic cancer model

This publication has 55 references indexed in Scilit:

• Batf3+ DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy
  Cell Reports, 2024
• Clinical immunotherapy in pancreatic cancer
  Cancer Immunology, Immunotherapy, 2024
• Oncolytic virus-based combination therapy in breast cancer
  Cancer Letters, 2024
• Oncolytic adenovirus as pancreatic cancer-targeted therapy: Where do we go from here?
  Cancer Letters, 2023
• Pancreatic cancer: Advances and challenges
  Cell, 2023
• Immunosuppression, immune escape, and immunotherapy in pancreatic cancer: focused on the tumor microenvironment
  Cellular Oncology, 2022
• PD-1/PD-L1 and immunotherapy for pancreatic cancer
  Cancer Letters, 2017
• Oncology Meets Immunology: The Cancer-Immunity Cycle
  Immunity, 2013
• Immune regulation and control of regulatory T cells by OX40 and 4-1BB
  Cytokine & Growth Factor Reviews, 2008
• Molecular cloning of a ligand for the inducible T cell gene 4‐1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor
  European Journal of Immunology, 1993